Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences' stock has experienced volatility in the past six months. The stock declined approximately 10% over the last 30 days due to market fluctuations and financing concerns, but rose about 12% over the past quarter due to positive earnings and pipeline progress. Key events impacting the stock include a Q4 2025 earnings beat, vispa-cel Phase 3 plans, CB-011 RMAT designation and clinical data, concerns about cash burn and capital needs, Q1 2026 financial results, and regaining Nasdaq compliance.

Caribou Biosciences does not currently have commercially available products, so there is no discernible demand seasonality. Demand will be driven by clinical trial outcomes, regulatory approvals, and eventual market adoption if its therapies are successfully commercialized.

Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing therapies for hematologic malignancies, solid tumors, and autoimmune diseases. The company uses its Cas12a chRDNA technology to develop allogeneic CAR-T cell therapies. Its major product candidates, all in Phase 1 clinical trials, include vispa-cel for B cell non-Hodgkin lymphoma, CB-011 for multiple myeloma, and CB-012 for acute myeloid leukemia. The company also generates revenue through collaboration and licensing agreements, such as with AbbVie.

Caribou Biosciences, Inc. is headquartered in Berkeley, California, United States. The company's operations are primarily in the United States, which accounts for the majority of its revenue, with additional operations in the rest of the world.

Caribou Biosciences' brand reputation is tied to its clinical progress, regulatory milestones, and financial standing. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $8.00. Positive events include positive clinical data from vispa-cel and CB-011, FDA designations for its therapies, and FDA alignment on the pivotal ANTLER-3 trial. The company's reputation is subject to the risks of clinical development, potential delays, and the need for additional financing.

Caribou Biosciences has a mixed ownership structure comprising institutional, insider, and retail investors. Major institutional owners include Pfizer Inc, Vanguard Group Inc, and BlackRock, Inc. Institutional investors hold approximately 0.68% to 14.13% of the company's stock, while insiders hold about 4.76%. Retail investors hold around 81.10%. Rachel E. Haurwitz, the CEO, owns the most shares among individual investors.